Ramipril and hydrochlorothiazide — Competitive Intelligence Brief

Ramipril and hydrochlorothiazide (Ramipril and hydrochlorothiazide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor and thiazide diuretic. Area: Cardiovascular.

phase 3 ACE inhibitor and thiazide diuretic ACE Cardiovascular Small molecule

Target snapshot

Ramipril and hydrochlorothiazide (Ramipril and hydrochlorothiazide) — Pfizer. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, while hydrochlorothiazide is a thiazide diuretic that increases urine production.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ramipril and hydrochlorothiazide TARGET	Ramipril and hydrochlorothiazide	Pfizer	phase 3	ACE inhibitor and thiazide diuretic	ACE
Ecclock	SOFPIRONIUM BROMIDE	Kaken Pharmaceutical	marketed		Muscarinic acetylcholine receptor M3	2024-01-01
Talvey	TALQUETAMAB	Janssen Biotech	marketed		T-cell surface glycoprotein CD3	2023-01-01
Epkinly	EPCORITAMAB	Genmab Us, Inc.	marketed	Bispecific CD20-directed CD3 T Cell Engager [EPC]	T-cell surface glycoprotein CD3	2023-01-01
Tzield	TEPLIZUMAB	Provention Bio Inc	marketed	CD3-directed Antibody [EPC]	T-cell surface glycoprotein CD3	2022-01-01
Candesartan Cilexetil	CILEXETIL	Alembic	marketed		Ace Inhibitor	2021-01-01
Mylotarg	GEMTUZUMAB	Wyeth Pharms Inc	marketed	CD33-directed Immunoconjugate [EPC]	Myeloid cell surface antigen CD33	2020-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor and thiazide diuretic class)

1. Pfizer · 1 drug in this class